

Company Overview

Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting

Apr 20 2021, 7:30 AM EDT

Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors

Apr 19 2021, 7:30 AM EDT

Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors

Mar 25 2021, 7:30 AM EDT

Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	152.52m
Last Price	\$1.54
52-Week	\$0.99 - \$3.79

05/07/2021 04:00 PM EDT

Investor Relations

ir@abeonatherapeutics.com

Management Team

Michael Amoroso

President, Chief Executive Officer

Jay Bircher

Chief Technical Officer

Edward Carr

Chief Accounting Officer, Principal Financial Officer

Jodie Gillon, M.P.H.

Chief Patient Officer

Greg Gin

Vice President, Investor Relations and Corporate Communications

Scott Nogi

Vice President, Business Operations

Brendan O'Malley, J.D., Ph.D.

Vice President, Head of Legal and IP

Juan Ruiz, M.D., Ph.D.

Head of European Medical Affairs

Abeona Therapeutics Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.